Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment

Research

Licensing

01:37 PM ET 07/09/2026

Arcutis Biotherapeutics (ARQT) is currently in a buy zone and looks to stretch a winning streak, with the IBD 50 stocks To Watch pick for Thursday, and skin-disorders treatment specialist, appearing set to broaden its product reach and bolster sales. The biotech stock on Thursday was on course for a fourth consecutive gain. During the run, Arcutis secured regulatory acceptance…

Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment

Other newsrooms on this story

Related reading

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View

Can Argenx Retake Its Record High On A New Vyvgart Strategy?

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific…

Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera…

What's Going on With Zura Bio Stock Wednesday? - Zura Bio (NASDAQ:ZURA)

Other newsrooms on this story

Related reading

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View

Can Argenx Retake Its Record High On A New Vyvgart Strategy?

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific…

Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera…

What's Going on With Zura Bio Stock Wednesday? - Zura Bio (NASDAQ:ZURA)